Lyudmila Bazhenova, MD, Discusses Potential for Trials Featuring Combination IO/Targeted Therapy for EGFR Exon 20+ and Wild Type NSCLC

Video

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Lyudmilia Bazhenova, MD, of University of California at San Diego, about why she would not recommend conducting another trial utilizing a single agent immune checkpoint inhibitor in wild-type and EGFR exon 20 insertion non–small cell lung cancer. However, she noted that there may be potential for a trial utilizing immunotherapy plus a lung cancer vaccine.

Transcript:

At this point I’m not aware of any of any trial, and I would be reluctant to do the trial with traditionally approved checkpoint inhibition because I think it’s unlikely that they’re going to work. If we would have a combinatorial immunotherapy trial of maybe a combination of lung cancer vaccines and immunotherapy, I think one can envision doing it. [However], in my practice, I do not use checkpoint inhibition for those patients, and I don’t think I would be comfortable enrolling the patient to a monotherapy immune checkpoint inhibition trial.

Reference

Bazhenova L, Girard N, Minchom A, et al. Comparative clinical outcomes between EGFR Exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Accessed September 27, 2021. Abstract P08.04

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content